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Other names: GP145-TrkB; TRKB; Trk-B 
Location: 9q21.33 
Local order: NTRK2 is located between solute carrier 
family 28, sodium-coupled nucleoside transporter 
member 3 (SLC28A3) and ATP/GTP binding protein 1 
(AGTPBP1). 
DNA/RNA 
Table 1: NTRK2 exons and size (bp). 
Description 
NTRK2 gene is comprised between 86,473,286-
86,828,325 bp of chromosome 9, with plus strand 
orientation. The start codon is located on exon 5. 
Alternative stop codons are placed on terminal exons 
16, 19 and 24. 
Transcription 
According to AceView (NCBI), six alternative 
promoters may control transcription of the complex 
NTRK2 locus. There are at least 18 mRNA variants 
supported by cDNA clones, potentially encoding 12 
complete proteins. Variants may include 8 different 
terminal exons with alternative polyadenylation site . 
Truncation at the 5' end or 3' end, alternative splicing, 
intron retention, occurrence of 5 cassette exons, ad 
different exon boundaries introduce additional 
differences. 
Five confirmed mRNA variants (a, b, c, d, e) are 
reported (NCBI accessions: NM_006180.3; 
NM_001007097.1; NM_001018064.1; 
NM_001018065.1; NM_001018066.1). The mRNA 
variant (a) encodes the full-length protein; variant (c) is 
slightly shorter excluding the small internal exon 17. 
Of particular importance are the truncated isoforms 
lacking the catalytic tyrosine kinase domain generated 
by the inclusion of alternate terminal exon 16 (b) or 




Note: Three TrkB isoforms are reported by 
UniProt/Swiss-Prot:  
1. The long isoform TrkB, including the tyrosine kinase 
domain (ID Q16620-1; variant c). 
2. The truncated isoform TrkB-T1 lacking the tyrosine 
kinase domain (ID Q16620-2; variant b). 
3. The truncated isoform TrkB-T-Shc lacking the 
tyrosine kinase domain but retaining the Shc site (ID 
Q16620-3; variant e). 
Description 
The unprocessed precursor of the full-length TrkB (a) 
consists of 838 AA. Variant (c) excludes 16 AA of 
unknown function, located downstream of the 
transmembrane segment. 
The N-terminal portion (AA 32-430) is potentially 
extracellular and includes several N-glycosylation sites 
(AA 67, 121, 254). It follows a single transmembrane 
segment (AA 432-454). The C-terminal portion is 
cytosolic (AA 455-822) and comprises the Protein 
Kinase domain. This region includes the ATP binding 
site (AA 544-552) and several sites of 
autophosphorylation such as Tyr-516/702/706/707/817 
(AA position refers to variant c). 
The truncated Trkb-T1 (b) is composed of 477 AA. 
TrkB-T-Shc variants d and e consist of 553 AA and 
537 AA, respectively. Truncated isoforms TrkB-T1 and 
TrkB-T-Shc include C-terminal sequence variations of 
10 and 9 AA, respectively. 
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Figure 1: The horizontal bar represents NTRK2 gene (355,039 bp). Vertical bars depict the exons 1-24 (red: translated regions, blue: 5' 
and 3' UTR regions). 
 
The predicted domains of TrkB (variant c): Signal Peptide (SP, AA 1-31); Leucine Rich Repeat N-Terminal domain (LRRNT, AA 31-65); 
Leucine-rich Repeats (LRR, AA 72-93, 96-117, 116-138); Leucine Rich Repeat C-Terminal domain (LRRCT, AA 148-195); 
Immunoglobulin C-2 Type 1 domain (IGC2-1, AA 197-282); Immunoglobulin C-2-type 2 domain (IGC2-2, AA 295-365); Transmembrane 
(TM, AA 431-454); the Protein Kinase domain (TyrKc, AA 538-807). In addition the site of interaction with SHC1 (Shc, AA 516) and with 
Phospho-Lipase C-gamma-1 (AA PLC-gamma, 817) are indicated. 
Expression 
NTRK2 gene is preferentially expressed in brain, spinal 
cord, cranial and spinal ganglia. Expression is most 
prominent in the following brain regions: amygdale, 
caudate nucleus, cerebellum, choroid plexus, corpus 
callosum, cortex, hippocampus, hypothalamus and 
thalamus. In addition, a variety of cranial structures 
such as eyes, ophthalmic nerves, various facial districts 
and vestibular system indicate significant expression. 
Lower expression is described in several other tissue  
such as heart, kidney, lung, ovaries, pancreas, pituitary 
gland, prostate, salivary glands, skeletal muscle, spleen, 
thymus and thyroid. 
Isoforms TrkB and TrkB-T1 are expressed in brain as  
well as in several peripheral areas, whereas TrkB-T-
Shc is primarily expressed in brain. 
AceView (NCBI) analysis of cDNA clones supports 
the expression pattern suggested by the evaluation of 
mRNA described above. In addition suggests elevated 
expression in several tumor tissues. 
Localisation 
Neuronal activity promotes TrkB translocation from 
intracellular vesicles to the plasma membrane where it 
becomes available for neurotrophins. The N-terminal 
segment is extracellular and is involved in neurotrophin 
binding and cell adhesion. A single transmembrane 
segment is located in the central portion of the 
polypeptide. The C-terminal segment is intracellular 
and comprises the protein kinase domain. 
Function 
TrkB specifically binds brain-derived neurotrophic 
factor (BDNF) and neurotrophin-4/5. It can also bind 
neurotrophin-3 with low affinity but it excludes nerv  
growth factor (NGF). Neurotrophin binding triggers 
receptor dimerization and consequent trans-
phosphorylation of tyrosine residues of the TyrKc 
domain. Phosphorylated receptor undergoes 
conformational changes, which promote the 
recruitment of intracellular substrates such SHC1, PI-3  
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kinase, and PLC-gamma-1. The signaling cascades 
consequently activated support neuronal survival 
during development and following injuries, promote 
neuronal differentiation and maintenance, control sh rt-
term and long-term synaptic activity. TrkB can also 
form heterodimers with the pan-neurotrophin receptor 
p75NTR or with truncated TrkB. This influences the 
establishment of specific connections with signaling 
pathways. 
Homology 
TrkB belongs to the large family of protein kinase 
comprising a conserved kinase domain. It is included in 
the subfamily of tyrosine protein kinase. For the 
presence of a highly conserved intracellular TyrKc 
domain it is most related to growth factor receptors, 
and particularly to the neurotrophic factor receptors 
TrkA and TrkC. The homology with tyrosine kinase 
receptors is extended to the IGC-2 and LRRs domains, 




Heterozygous missense mutations leading to 
substitution of highly conserved residues have been 
linked to Obesity, Hyperphagia and Developmental 
Delay. 
Recurrent SNPs of the NTRK2 locus are associated 
with Eating Disorders (Anorexia and Bulimia nervosa). 
Somatic 
Tumor-specific mutations in the kinase domain have 




Obesity, Hyperphagia and Developmental Delay. 
Neuroblastomas, Pancreatic Ductal Adenocarcinomas, 
Wilms's tumors, Colorectal Cancer. 
Oncogenesis 
Overexpression of full-length TrkB is generally 
associated with malignant transformation. Excessive 
TrkB signaling through MAPK, PI3K and mTOR 
pathways support tumor development and metastasis. 
In highly malignant tumors the overexpression of TrkB 
enhances angiogenesis and invasive potential by 
upregulating VEGF and matrix proteases. Furthermore 
TrkB overcomes apoptosis caused by loss of cell-
matrix interactions (anoikis), which is a natural brrier 
to metastasis. 
In contrast with the oncogenic activity of TrkB, the 
truncated isoforms TrkB-T1 and TrkB-T-Shc, lacking 
the tyrosine kinase domain, behave as dominant-
negative inhibitors and counteract tumor growth. 
To be noted 
Note: NTRK2 gene is comprised in the region, del(9q), 
commonly deleted in acute myeloid leukemia, this 
disease is believed to arise by heterozygous loss of 
tumor suppressor genes. 
Numerous structural abnormalities of the region 9q22 
are associated with cancer cases reported by The 
Cancer Genome Anatomy Project (CGAP). 
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